<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175029</url>
  </required_header>
  <id_info>
    <org_study_id>10054040</org_study_id>
    <nct_id>NCT03175029</nct_id>
  </id_info>
  <brief_title>Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.</brief_title>
  <official_title>Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor
      underactivity patients with overactive bladder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to assess the efficacy of TAC-302 for 12 weeks in detrusor
      underactivity patients with overactive bladder by measuring the following parameters of
      pressure-flow study.

        -  Male; bladder contractility index (BCI)

        -  Female; projected isovolumetric pressure (PIP) 1
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Male; bladder contractility index (BCI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pressure-flow study parameters of the detrusor pressure at maximum flow rate (PdetQmax) and the maximum flow rate (Qmax) will be combined to report BCI.
BCI=PdetQmax + 5Qmax The detrusor pressure at maximum flow rate (PdetQmax) in centimeters water, the maximum flow rate (Qmax) in milliliters per second.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Female; projected isovolumetric pressure (PIP) 1</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pressure-flow study parameters of the detrusor pressure at maximum flow rate (PdetQmax) and the maximum flow rate (Qmax) will be combined to report PIP1.
PIP1=PdetQmax + Qmax The detrusor pressure at maximum flow rate (PdetQmax) in centimeters water, the maximum flow rate (Qmax) in milliliters per second.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bladder capacity of first desire to void</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The urodynamic parameter of pressure-flow study during filling phase Bladder capacity of first desire to void in milliliters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder compliance</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The urodynamic parameter of pressure-flow study during filling phase Bladder compliance in milliliters per centimeters water</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appearance of bladder involuntary contraction</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The urodynamic parameter of pressure-flow study during filling phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qmax</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The urodynamic parameter of pressure-flow study during voiding phase Qmax in milliliters per second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PdetQmax</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The urodynamic parameter of pressure-flow study during voiding phase PdetQmax in centimeters water</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder contraction duration</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The urodynamic parameter of pressure-flow study during voiding phase Bladder contraction duration in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum free flow rate (free Qmax)</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>The urodynamic parameter of free uroflowmetry Free Qmax in milliliters per second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voided volume</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>The urodynamic parameter of free uroflowmetry Voided volume in milliliters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voiding time</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>The urodynamic parameter of free uroflowmetry Voiding time in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Void Residual</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Determining the volume of post void residual by ultrasonography Post Void Residual in milliliters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder Voiding Efficiency (BVE)</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Voided volume and Post Void Residual will be combined to report BVE BVE(%)=[Voided volume/(Voided volume+ Post Void Residual)]×100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the international prostate symptom score (IPSS)</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the overactive bladder symptom score (OABSS)</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the king's health questionnaire (KHQ)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in mean urinary frequency per day, mean frequency of urgency and urge urinary incontinence episodes per day</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>The bladder diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence rate and severity of adverse events</measure>
    <time_frame>Up to 13 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Detrusor Underactivity</condition>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>TAC-302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAC-302</intervention_name>
    <description>TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.</description>
    <arm_group_label>TAC-302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally twice per day after meals, for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  To have Lower Urinary Tract Symptoms for at least 12 weeks prior to study entry

          -  To have at least 1 urinary urgency episodes per day, and diurnal urinary frequency of
             8 or more per day.

          -  To meet the detrusor underactivity criteria by urodynamic study

        Key Exclusion Criteria:

          -  Neurogenic bladder by the central nervous system diseases.

          -  StageIII or more cystocele of pelvic organ prolapse quantification system (women)

          -  Prostate volume ≥30mL (Men)

          -  Any symptoms of Urinary tract infection (UTI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiho Pharmaceutical Co., Ltd</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-3294-4527</phone>
    <email>toiawase@taiho.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taiho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Hypokinesia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

